🚨Here we go🚨#PRIME trial in @JAMA_current today. Short biparametric MRI without contrast injection non-inferior to multiparametric MRI with contrast, c.sig PCa 29.2 vs 29.6%. n=555, 12 countries, 22 centres. Possible new standard for Pca diagnosis! 1/4

Whether it's a routine checkup or highly specialized care, Yale Urologists and caregivers provide the most advanced treatment, grounded in research. Find out more ➡️ https://t.co/M8L758NtC7 #UrologyAwarenessMonth @YaleMed|@YaleMedicine

📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4

🚨 New in @urogoldjournal ✒️Lead author chief resident @john_r_heard 🩸Hematuria Cancer Risk Score (HCRS) + Oncuria-Detect urine test improves #bladdercancer detection 🔬AUC 0.91 👉May cut cystoscopies by up to 70% @CSCancerCenter @urotoday 🔗 https://t.co/Md07xBT9Yp

On behalf of the IBCG Board, thank you to all who joined us from across the globe for #IBCG25 Your expertise, energy, and commitment made this a true success. It was a joy to see familiar faces and new ones alike, and to share in the lively debates and genuine camaraderie that

🚨New in @BJUIjournal Study on IR-NMIBC: - 0 IBCG RF → induction only sufficient - 1–2 RF → 35% ↓ recurrence w/ maintenance - ≥3 RF → 52% ↓ recurrence w/ maintenance IBCG stratification may guide risk-adapted therapy Full text👉 https://t.co/ggcLtDZEqd #BladderCancer

Heading home after an outstanding #IBCG25 - inspiring to be w/ colleagues driven to improve #bladdercancer care. Great catching up with friends, inc fellow 🇬🇧 @achoud72 @Heer_Lab (+ ex 🇬🇧 @drtanws!) Congrats to the entire @IBCG_BladderCA committee @UroDocAsh

TURBT may have a higher risk of adverse events than is often appreciated. Costs of TURBT are also substantial at a system level. Limitations of administrative data apply. great team effort. JJ Zhang @DDJoyce_BFA @AnthonyFadelMD @SWilliams_MD Yong Shan @UTMBUrology

Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25! Together we’ll focus on two crucial goals: integrating bladder cancer biomarkers into clinical practice, and developing tools to better monitor and address local bladder toxicity - guided

Just published online in @JCO_ASCO : #SunRISe1 Phase IIb results show TAR-200 (novel intravesical drug releasing system) achieves 82.4% CR in BCG-unresponsive high-risk NMIBC—with durable responses (median DOR 25.8 mo) & low toxicity. A game-changer for pts with #NMIBC.

J&J receives @US_FDA Priority Review for TAR-200 in high-risk NMIBC Phase 2b SunRISe-1 study #AUA25 ✅82.4 % CR rate ☑️ 52.9 % cancer-free at least one year after CR https://t.co/jMtTd90T7x

🩸💥 Many have asked: “Where did the EAU #thromboprophylaxis guideline go?” Don’t worry. Check out https://t.co/5raiSR20pn 🚀 ✅ Not just #urology, also #gynecology & abd #surgery ✅ Procedure-specific VTE & bleeding risks ✅ Free interactive tool + static infographics #EBM

Chech out our study on TMT vs. RC for #MIBC a (long) 🧵(with some stats) https://t.co/Z3G1ySwXFr @CHematology @DRobesti @GPloussard @GFallara_MD @uofcincycancer @OncoAlert @OncLiveSOSS @Uroweb @EauGuidelines @AmerUrological @UroOnc

🚨 NEW in #EuropeanUrology By @saumyg @UrogerliMD @spsutkaMD @tbivala1 @joanfundi et al Can novel intravesical therapies change the game for non–muscle-invasive bladder cancer? This systematic review explores: ✅ BCG-based combos ✅ Gene & immune therapies ✅ Innovative drug

1/8 🎉Thrilled to share our landmark study now published in @TheLancet on a capsule sponge surveillance strategy for Barrett's oesophagus https://t.co/PR1hyLoAfl presented at the @BritSocGastro, Glasgow @Cambridge_Uni @EarlyCancerCam @addenbrookes @CR_UK @RFitzgerald_lab

New data on hydro TMT in MIBC 🚨guess that’s why it’s not ideal 👎 📊 74% of patients with pre-existing hydronephrosis still had it post-TMT 💧 21% of patients WITHOUT hydronephrosis developed it after TMT 🧵 52% of new cases needed PCNT drainage…. https://t.co/zh0KLs6y2m

🚨 NEW #PlatinumOpinion in European Urology by M. J. Roberts, @GGandaglia et al : 💡 Is extended pelvic lymph node dissection (ePLND) still justified in prostate cancer? 📉 No oncologic benefit in RCTs ⚠️ Up to 20% complication rate 🧬 PSMA PET reshapes staging 🔄 2024 EAU

A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol https://t.co/trmFp9Yd0y There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

Our take on radiation for NMIBC in @EUplatinum @saumyg @MelindaFu3 https://t.co/6zIsdlLBRw

📰👀Finger test ‘has no role in diagnosing prostate cancer today’ We, alongside @ProstateUK, have united in calling for an end to the routine use of the digital rectal examination, with it no longer being a useful test for #ProstateCancer Via @thetimes: https://t.co/6W7Ra7Jrl1